CASI Pharmaceuticals (NASDAQ: CASI) has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD).
Dr. Krebs-Pohl brings more than 27 years of leadership experience in the biotechnology space to the role—particularly in development, business strategy, and alliance creation. She is currently the managing director of the Foundation for Stem Cell Research and Regenerative Medicine, as well as a partner and managing director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth and strategic partnerships.
In a statement, Dr. Krebs-Pohl said, in part, “I am thrilled to be joining CASI at such an important stage, with the recent FDA IND acceptance for CID-103 for antibody-mediated rejection.”
David Cory, CEO of CASI, commented, “As our CID-103 program continues to evolve and deliver additional data to support targeting CD38 across clinical patient populations and indications, we expect Barbara’s background and strategic insights at the board level will be invaluable to the CASI operating team.”
